10-Q: PacBio Q3 2025: Losses Widen Amid Restructuring & Asset Write-Downs

Pacific Biosciences reports a slight revenue increase to $115.4 million for the nine months ended September 30, 2025, but operating loss significantly widens to $512.7 million due to substantial restructuring charges and asset impairments.

Summary

• Total revenue for the nine months ended September 30, 2025, was $115.4 million, a slight increase from $114.8 million in the same period of 2024.
• Product revenue decreased by 5% to $96.8 million for the nine months ended September 30, 2025, primarily due to a 28% decrease in instrument revenue (40 Revio units sold vs. 74 in 2024), partially offset by a 17% increase in consumable revenue.
• Service and other revenue increased by 46% to $18.6 million for the nine months ended September 30, 2025, driven by Revio service contracts.
• Gross profit increased by 7% to $29.2 million for the nine months ended September 30, 2025, compared to $27.2 million in 2024.
• Operating loss significantly widened to $512.7 million for the nine months ended September 30, 2025, compared to $321.3 million in the same period of 2024.
• This increase in operating loss was primarily due to $382.4 million in restructuring-related costs, including $359.3 million in accelerated amortization of acquired intangibles and $15.0 million in IPR&D impairment charges.
• Net loss for the nine months ended September 30, 2025, was $506.0 million, compared to $312.2 million in the same period of 2024.
• Cash, cash equivalents, and investments decreased by 23% to $298.7 million at September 30, 2025, from $389.9 million at December 31, 2024.
• The company ceased development of its high-throughput short-read system, leading to a $18.7 million change in the fair value of contingent consideration liability to $0.
• 98 Vega benchtop long-read sequencing systems were sold during the nine months ended September 30, 2025, following its commercial launch in Q4 2024.

Sentiment

Score: 3

Explanation: While there's slight revenue growth and strong consumable sales, the substantial increase in net and operating losses due to significant impairment and accelerated amortization charges, coupled with declining instrument sales and ongoing cash burn, indicates significant financial challenges and costly strategic shifts. The need for potential future capital raises and elongated sales cycles for key products further contribute to a negative sentiment.

Positives

• Total revenue for the nine months ended September 30, 2025, saw a slight increase to $115.4 million from $114.8 million in 2024.
• Consumables revenue increased by 17% to $60.3 million for the nine months ended September 30, 2025, reflecting the expanding Revio installed base.
• Service and other revenue increased significantly by 46% to $18.6 million for the nine months ended September 30, 2025, driven by Revio service contracts.
• Gross profit increased by 7% to $29.2 million for the nine months ended September 30, 2025, compared to $27.2 million in 2024.
• Successful commercial launch of the Vega benchtop platform in Q4 2024, with 98 units sold in the nine months ended September 30, 2025.
• Net cash used in operating activities significantly decreased to $92.1 million for the nine months ended September 30, 2025, from $175.4 million in the same period of 2024.
• Existing cash, cash equivalents, and investments of $298.7 million are believed to be sufficient to fund projected operating requirements beyond the next 12 months.

Negatives

• Product revenue decreased by 5% to $96.8 million for the nine months ended September 30, 2025.
• Instrument revenue decreased by 28% to $36.5 million for the nine months ended September 30, 2025, with Revio unit sales dropping from 74 to 40 units.
• Operating loss significantly widened to $512.7 million for the nine months ended September 30, 2025, from $321.3 million in 2024.
• Net loss for the nine months ended September 30, 2025, was $506.0 million, a substantial increase from $312.2 million in 2024.
• Significant restructuring-related costs of $382.4 million were incurred, including $359.3 million in accelerated amortization of acquired intangibles and $15.0 million in IPR&D impairment charges.
• Cash, cash equivalents, and investments decreased by 23% to $298.7 million at September 30, 2025, from $389.9 million at December 31, 2024.
• The company ceased development of its high-throughput short-read system, leading to a $18.7 million write-down of contingent consideration liability to $0, indicating a failure to achieve the acquisition milestone.
• The sales cycle for Revio instrument purchases continues to be elongated due to funding uncertainty (NIH, academic), procurement delays, and slower-than-expected sample volumes.
• The company expects to continue to incur substantial losses and negative cash flow from operations for the foreseeable future and does not expect to be profitable in 2025.

Risks

• Inability to successfully market, commercialize, and sell current and future products and related maintenance services.
• Inability to achieve profitability for the business.
• Inability to implement required expense reduction initiatives successfully.
• Inability to repay debt and fund long-term operations.
• Inability to successfully leverage and integrate acquisitions and future acquisitions.
• Inability to successfully research, develop, and timely manufacture current and future products.
• Challenges in managing new product introductions and transitions, resultant costs, and ensuring new products generate promised performance.
• Disruptions to business due to recent significant changes to the leadership team.
• Difficulties in retention, recruitment, and training of senior management, key personnel, scientists, and engineers.
• Inability to further penetrate nucleic acid sequencing applications and grow product demand.
• Reliance on outsourcing to other companies for manufacturing certain products, components, and sub-assemblies, some of which are sole-sourced.
• Impact of tariffs and other trade protection measures, import/export licensing requirements, customs duties, trade embargoes, and sanctions.
• Inability to consistently manufacture instruments and consumables to meet customer specifications, quantity, cost, or performance requirements.
• High competition in the industry.
• Inability to attract customers and increase sales of current and future products.
• Reliance on a limited number of customers for a significant portion of revenues, including academic, research, and government institutions, which may be impacted by funding reductions.
• Complexity of products leading to defects or errors.
• Unpredictable and lengthy sales cycles.
• Potential impairment of goodwill or intangible assets.
• Adverse effects from political and economic tensions between the United States and other countries (e.g., China, Russia) and other geopolitical uncertainties.
• Challenges in securing and maintaining patent or other intellectual property protection.
• Current and future legal proceedings claiming intellectual property infringement.
• Potential adverse impact of health epidemics.
• Potential cybersecurity incidents and security breaches.
• Governmental regulations burdening operations or narrowing the market for products.
• Evolving ethical, legal, privacy, social, and regulatory concerns regarding genetic testing.
• Volatility of the common stock price.
• Stock price falling as a result of future offerings or sales of securities.
• Inability to raise funds necessary to settle conversions of Notes in cash or to repurchase Notes upon a fundamental change.
• Operating restrictions imposed by the Side Letter to the 2029 Notes.
• Adverse effects on financial condition and operating results if Notes are converted.
• Encouragement of short selling due to the existence of the Notes.
• Unfavorable global economic or political conditions.
• Delays or disruptions in product delivery by third-party carriers.
• Operational and financial risks associated with doing business outside of the United States.
• Failure to maintain proper and effective internal controls.
• Negative impact from changes in the United States political environment (e.g., NIH funding cuts).
• Reputational harm or liability from the use of artificial intelligence and machine learning technologies.
• Increased costs and risks from scrutiny of environmental, social, or governance responsibilities.

Future Outlook

The company's 2025 strategic objectives are to grow revenue and expand gross margins by enabling the full-scale release of the Vega benchtop platform, accelerating samples onto the Revio platform via SPRQ chemistry and application kits (aiming for sub-$500 HiFi genome, improved methylation detection, 75% DNA input reduction), investing in future product launches to diversify offerings, and progressing its clinical strategy. The company expects continued growth in consumables revenue as adoption of the Revio and Vega platforms expands, but anticipates instrument revenue may fluctuate quarter-to-quarter. Significantly lower amortization expense is expected in future periods after the recent accelerated amortization. The company believes its existing cash, cash equivalents, and investments will be sufficient to fund projected operating requirements beyond the next 12 months, but expects to continue incurring substantial losses and negative cash flow from operations for the foreseeable future and does not expect to be profitable in 2025, potentially requiring additional capital resources.

Management Comments

• Our 2025 strategic objectives are to grow revenue and expand gross margins through the following four activities: Enabling the full-scale release of the Vega benchtop platform to broaden our market reach; Accelerating samples onto the Revio platform via SPRQ chemistry and application kits; Investing in future product launches to diversify our offerings; Progressing our clinical strategy to improve outcomes and create durability.
• We believe the Vega platform broadens the long-read market opportunity.
• The SPRQ chemistry enables the sub-$500 HiFi genome, improves methylation detection capabilities, and achieves a 75% reduction in DNA input requirements for human whole genome sequencing. These features can drive more samples onto HiFi sequencing than ever before.
• We continue to develop sequencing systems designed to increase throughput and lower the cost to sequence a genome, which we believe will allow us to address an even larger part of the market.
• We continue to believe that with the capabilities of our HiFi chemistry and SMRT technology, we can be a market leader in whole-genome clinical sequencing.
• We believe the market opportunity for clinical sequencing is significant and could drive substantial revenue growth for the Company.
• The sales cycle for Revio instrument purchases continues to be elongated. We believe this has been caused by, among other reasons, the uncertainty surrounding the funding for new capital equipment, in particular, uncertainty in the United States related to the National Institutes of Health ('NIH') and academic funding; procurement delays; small-to-mid-size existing customers yet to increase their sample volumes to drive an upgrade to Revio; new customers, which have shown they have longer sales cycles compared to existing PacBio customers; and sample volumes materializing slower than expected for some potential Revio customers.
• We have historically incurred, and expect to continue to incur, operating losses and generate negative cash flows from operations on an annual basis, and as a result, we may require additional capital resources to execute our strategic initiatives to grow our business.
• We believe that our existing cash, cash equivalents and investments will be sufficient to fund our projected operating requirements beyond the next 12 months from the date of filing of this Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• We do not expect to be profitable in 2025, and there can be no assurance that these expense reduction initiatives will be successful in helping us achieve profitability.

Industry Context

The life sciences industry, particularly genomic sequencing, is characterized by rapid technological advancements and intense competition. PacBio's focus on HiFi long-read sequencing aligns with a technology recognized for its contributions to biological understanding. However, the company operates in a challenging funding environment, especially for capital equipment purchases by academic and research institutions, which is a common industry headwind. The strategic pivot away from short-read technology, as evidenced by the cessation of the high-throughput short-read system development, suggests a consolidation of focus in a highly competitive market dominated by both established players and new entrants.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• U.S. District Court Proceedings: Personal Genomics of Taiwan, Inc. (PGI) filed a patent infringement complaint (C.A. No. 19-cv-1810) against PacBio on September 26, 2019, alleging infringement of U.S. Patent No. 7,767,441 by Sequel and Sequel II systems. The case was stayed pending IPRs, which were affirmed by the Federal Circuit on January 9, 2024. The case was transferred to the Northern District of California on June 18, 2024, with a trial date set for October 5, 2026. PacBio plans to vigorously defend against the remaining claims.
• Other Proceedings: The company may be involved in various other claims, lawsuits, investigations, and proceedings related to securities laws, product liability, patent infringement, contract disputes, employment, and other matters in the ordinary course of business. The company does not believe the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on its business.

Related Party Transactions

• On November 7, 2024, the company entered into an exchange agreement with SB Northstar LP (SBN), a subsidiary of SoftBank Group Corp. (a principal stockholder), to exchange approximately $459.0 million of 2028 Convertible Senior Notes for $200.0 million of 2029 Convertible Senior Notes, 20,451,570 shares of common stock, and $50.0 million of cash. The 2029 Notes are subject to certain debt and lien covenants and springing guarantees as per a second letter agreement with SBN. As of September 30, 2025, the company was in compliance with all covenants under the Letter Agreement.

Stakeholder Impact

• Shareholders: Significant net losses and operating losses could negatively impact share price. Potential future capital raises could dilute existing ownership. Volatility of stock price is a risk. Anti-takeover provisions may limit ability to influence management/board. No dividends expected in the foreseeable future. Concentration of ownership by principal stockholders may limit influence.
• Employees: Workforce reductions in 2024 and 2025 as part of expense reduction initiatives. Risk of difficulty in attracting/retaining employees due to reductions or stock price declines. Leadership transitions could disrupt operations and morale.
• Customers: Elongated sales cycles for Revio instruments due to funding uncertainty and procurement delays. Potential for product defects or errors could lead to dissatisfaction and loss of sales. Reliance on a limited number of large customers makes revenue vulnerable to their purchasing decisions. Introduction of new products (Vega, SPRQ chemistry) aims to broaden market reach and drive adoption. Cessation of high-throughput short-read system development means no future products from Apton acquisition in that area.
• Suppliers/Partners: Reliance on sole-source suppliers for critical components poses supply chain risks. Trade tariffs and geopolitical tensions (US-China, Taiwan) could disrupt supply chains and increase costs. Need to maintain strategic relationships with vendors and manufacturers.
• Creditors (Note Holders): Company has significant convertible senior notes ($200M due 2029, $441M due 2030). Risk of company not having sufficient cash to settle conversions or repurchase notes upon fundamental change. Covenants in the 2029 Notes (Letter Agreement with SBN) impose operating restrictions.

Next Steps

• Full-scale release of the Vega benchtop platform to broaden market reach.
• Accelerating samples onto the Revio platform via SPRQ chemistry and application kits.
• Investing in future product launches to diversify offerings.
• Progressing clinical strategy to improve outcomes and create durability.
• Continue to pursue partner collaborations where technologies or applications extend beyond whole-genome clinical sequencing.
• Vigorously defend against remaining claims in the PGI patent infringement lawsuit, with a trial date set for October 5, 2026.
• Monitor the U.S. District Court case regarding the FDA's LDT final rule and any future legislative/administrative actions.
• Evaluate compliance needs for data privacy and security, including potential additional internal/external audits and policies for third-party vendors.

Key Dates

Recommendation

The company reported a substantial widening of its net loss to $506.0 million for the nine months ended September 30, 2025, primarily due to $382.4 million in restructuring-related costs, including significant impairment and accelerated amortization charges. This indicates a major write-down of previous investments and a costly strategic pivot. While consumables revenue is growing and the Vega system is launching, the significant decline in Revio instrument sales (down 28%) suggests challenges in monetizing its flagship long-read platform. The company continues to burn cash, with cash and investments decreasing by 23%, and explicitly states it expects to incur substantial losses and negative cash flow for the foreseeable future, not expecting profitability in 2025. The need for potential future capital raises, coupled with an already volatile stock price and operating restrictions from existing debt, presents considerable downside risk for investors. The strategic shift away from the acquired Apton short-read technology also signals a failure in a previous growth initiative.

Keywords

Genomic sequencing, HiFi long-read sequencing, Revio system, Vega benchtop system, Consumables, Biotechnology, Life sciences, SEC 10-Q, Financial results, Restructuring, Impairment charges, Convertible notes, Research and development, Clinical sequencing, Corporate governance, Risk factors